Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...

During a Community Case Forum series, breast cancer experts discussed the importance of testing for ESR1 mutations, in ...

The most common breast cancer is HER2-negative, so called because it has low amounts of one of the proteins that contribute to tumor cell growth, HER2. Despite this common trait, the development of ...

As Enhertu’s reach continues to spread into additional forms of breast cancer, Daiichi Sankyo and AstraZeneca are ramping up ...

If you or a loved one have breast cancer, you are not alone. With support groups at local hospitals and the Susan G. Komen’s ...